Altaris

• Clarivate to Divest Life Sciences & Healthcare Segment to Altaris for $600 Million

  July 6, 2026

  Buyer

  Altaris LLC

  Target

  Clarivate Life Sciences & Healthcare segment

  Seller

  Clarivate Plc

  Industry

  Healthcare Services

  Location

  United States

  Type

  Divestiture

  Clarivate Plc entered into a definitive agreement to divest its Life Sciences & Healthcare segment to Altaris LLC for $600 million. Proceeds are intended to be used primarily to reduce debt, with closing expected by the end of the year subject to customary conditions.

• Altaris Acquires Simulations Plus for Approximately $375 Million

  June 17, 2026

  Buyer

  Altaris, LLC

  Target

  Simulations Plus, Inc.

  Industry

  Software

  Location

  North Carolina, United States

  Type

  Buyout

  Simulations Plus has entered into a definitive agreement to be acquired by affiliates of Altaris in an all-cash transaction valued at approximately $375 million. Stockholders will receive $18.50 per share, a 26% premium to the company’s 60-day volume-weighted average price as of June 15, 2026.

• Leidos and Altaris to Combine Security Enterprise Solutions with Analogic Under Analogic Leadership

  April 15, 2026

  Buyer

  Leidos, Inc., Analogic Corporation, Altaris

  Target

  Leidos Security Enterprise Solutions (SES), Analogic Corporation

  Industry

  Cybersecurity

  Location

  New Hampshire, United States

  Type

  Buyout

  Leidos Security Enterprise Solutions (SES) is set to combine with Analogic, with the combined global security imaging and detection business operating under the Analogic brand. Leidos and investment firm Altaris entered into a joint venture agreement, with the transaction expected to close in the second half of 2026, subject to approvals and customary conditions.

• Altaris Acquires Tegria Services Group from Providence St. Joseph Health

  January 6, 2026

  Buyer

  Altaris, LLC

  Target

  Tegria Services Group, Inc.

  Seller

  Providence St. Joseph Health

  Industry

  Healthcare Services

  Location

  Washington, United States

  Type

  Buyout

  Altaris has completed the acquisition of Tegria Services Group, Inc. from Providence St. Joseph Health, establishing Tegria as a standalone, Altaris‑backed portfolio company that will continue to serve Providence as a preferred technology services partner. The deal positions Altaris to expand its healthcare services and technology platform capabilities—supporting providers and payers with consulting, managed services, data & analytics, and revenue cycle management.

• Altaris Acquires WuXi AppTec's Advanced Therapies U.S. and U.K. Operations (including OXGENE)

  December 24, 2024

  Buyer

  Altaris, LLC

  Target

  Advanced Therapies (U.S. and U.K. operations of WuXi AppTec's Advanced Therapies Unit), OXGENE

  Seller

  WuXi AppTec

  Industry

  Biotechnology

  Location

  Pennsylvania, United States

  Type

  Addon

  Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.

• Altaris Acquires Minaris Regenerative Medicine from Resonac

  September 23, 2024

  Buyer

  Altaris, LLC

  Target

  Minaris Regenerative Medicine

  Seller

  Resonac Corporation, Resonac Holdings Corporation

  Industry

  Healthcare Services

  Location

  Pennsylvania, United States

  Type

  Buyout

  Altaris, LLC has acquired Minaris Regenerative Medicine from Resonac Corporation, making Minaris a wholly owned portfolio company of Altaris. Minaris is a cell therapy CDMO with six facilities across the United States, Germany and Japan and more than 500 employees; the deal advances Altaris' strategic initiative to build capabilities in cell and gene therapy manufacturing.

• Altaris Acquires Sharecare

  June 25, 2024

  Buyer

  Altaris, LLC

  Target

  Sharecare, Inc.

  Seller

  Sharecare stockholders

  Industry

  Healthcare Services

  Location

  Georgia, United States

  Type

  Buyout

  Altaris, a healthcare-focused investment firm, agreed to acquire publicly traded digital health company Sharecare in a take-private transaction at $1.43 per share. The deal will take Sharecare private (stockholders approved the transaction) and positions the company to operate as a standalone portfolio company under Altaris to accelerate growth and product/service development.

• Kindeva Drug Delivery Acquires Summit Biosciences

  January 18, 2024

  Buyer

  Kindeva Drug Delivery, Altaris, LLC

  Target

  Summit Biosciences, Summit Biosciences Inc.

  Seller

  Summit’s founding family shareholders

  Industry

  Healthcare Services

  Location

  Kentucky, United States

  Type

  Buyout

  Kindeva Drug Delivery, an operating company of Altaris, LLC, acquired Summit Biosciences, a specialized intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. The deal expands Kindeva’s drug-delivery capabilities with a new intranasal drug-delivery platform and adds Summit’s FDA- and EMA-approved cGMP facility in Lexington, Kentucky.

• Altaris Acquires Trean Insurance Group

  April 18, 2023

  Buyer

  Altaris, LLC

  Target

  Trean Insurance Group, Inc.

  Seller

  Trean's remaining public common stockholders

  Industry

  Insurance

  Location

  Minnesota, United States

  Type

  Buyout

  Altaris, LLC completed a take-private acquisition of Trean Insurance Group, Inc., acquiring the remaining publicly held shares for $6.15 per share in a transaction that implied an approximate $316 million equity value. Trean will remain headquartered in Wayzata, Minnesota, with Julie Baron continuing as President and CEO and founder Andrew O'Brien remaining as Executive Chairman and an investor; Trean will cease trading on Nasdaq following the closing.

• Chemical Computing Group Acquires Discngine

  December 22, 2022

  Buyer

  Chemical Computing Group ULC, Altaris, LLC

  Target

  Discngine SAS

  Industry

  Software

  Location

  Île-de-France, France

  Type

  Addon

  Chemical Computing Group ULC (an Altaris operating company) has acquired Paris-based Discngine SAS, a provider of cheminformatics, structural bioinformatics and lab informatics software and services for life sciences research. The deal will add Discngine as a subsidiary of CCG, bolstering CCG's technical science capabilities and creating synergies across their life-sciences software offerings.

• Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

  December 13, 2022

  Buyer

  Altaris, LLC, Kindeva Drug Delivery

  Target

  Meridian Medical Technologies

  Industry

  Medical Devices

  Location

  Missouri, United States

  Type

  Addon

  Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.

• Solesis Acquires Polyzen

  November 3, 2022

  Buyer

  Solesis, Altaris

  Target

  Polyzen

  Industry

  Medical Devices

  Location

  North Carolina, United States

  Type

  Addon

  Solesis, an operating company backed by Altaris, has acquired Polyzen, a contract developer and manufacturer of polymer-based films, coatings, components and assemblies for the medical device and biopharmaceutical markets. Polyzen will operate as a subsidiary of Solesis, expanding Solesis' polymer film and coating capabilities to better serve medical device, bioprocessing, drug delivery and cell and gene therapy customers.

Related Acquisition Pages